Connor, Clark & Lunn Investment Management (CC&L)’s Cymabay Therapeutics CBAY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-104,271
| Closed | -$1.14M | – | 1597 |
|
|
2023
Q2 | $1.14M | Sell |
104,271
-236,367
| -69% | -$2.59M | 0.01% | 755 |
|
|
2023
Q1 | $2.97M | Buy |
340,638
+50,464
| +17% | +$440K | 0.02% | 470 |
|
|
2022
Q4 | $1.82M | Buy |
290,174
+25,112
| +9% | +$157K | 0.01% | 561 |
|
|
2022
Q3 | $928K | Buy |
265,062
+119,149
| +82% | +$417K | 0.01% | 678 |
|
|
2022
Q2 | $430K | Buy |
145,913
+78,692
| +117% | +$232K | ﹤0.01% | 814 |
|
|
2022
Q1 | $209K | Buy |
+67,221
| New | +$209K | ﹤0.01% | 937 |
|
|
2021
Q1 | – | Sell |
-88,837
| Closed | -$510K | – | 1121 |
|
|
2020
Q4 | $510K | Sell |
88,837
-95,557
| -52% | -$549K | ﹤0.01% | 722 |
|
|
2020
Q3 | $1.34M | Sell |
184,394
-60,936
| -25% | -$441K | 0.01% | 564 |
|
|
2020
Q2 | $856K | Buy |
245,330
+128,755
| +110% | +$449K | 0.01% | 647 |
|
|
2020
Q1 | $173K | Buy |
116,575
+88,925
| +322% | +$132K | ﹤0.01% | 883 |
|
|
2019
Q4 | $54K | Buy |
+27,650
| New | +$54K | ﹤0.01% | 896 |
|